- Investor Relations
A current pharma customer recently ordered its third HoloMonitor® unit. The ordered configuration is the automated stage version of the HoloMonitor platform. The total retail price of the ordered units amounts to €90 000.
“The follow-up order from a world leading Swiss pharma company confirms the market potential within Big Pharma and the pharmaceutical industry in general. Big Pharma’s interest shows that our HoloMonitor technology is rapidly becoming established and highlight the importance of our goal to create a Center of Excellence in the Basel area”, said CEO Peter Egelberg.
The pharmaceutical industry in Switzerland directly and indirectly employs close to 170 000 people and approximately contributes with 30% of the country’s exports. Basel is the home of two largest Big Pharma companies in the world, Novartis and Roche.